Start Time: 08:30 January 1, 0000 9:30 AM ET
Compugen Ltd. (NASDAQ:CGEN)
Q3 2024 Earnings Call
November 12, 2024, 08:30 AM ET
Company Participants
Anat Cohen-Dayag - President and CEO
David Silberman - CFO
Michelle Mahler - Chief Medical Officer
Eran Ophir - Chief Scientific Officer
Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program
Yvonne Naughton - Head of IR and Corporate Communications
Conference Call Participants
Stephen Willey - Stifel
Daina Graybosch - Leerink Partners
Tony Butler - Rodman and Renshaw
Asthika Goonewardene - Truist Securities
Operator
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investor section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded.
I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.
Yvonne Naughton
Thank you, Yoni, and thank you all for joining us on the call today. Joining me from Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; David Silberman, Chief Financial Officer; and Dr. Michelle Mahler, Chief Medical Officer. We're also delighted to be joined by Dr. Oladapo Yeku, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program, Massachusetts General Hospital, Boston. He was also an investigator on our triple IO combination ovarian cancer study, which we'll discuss today. Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.
Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcome, the company's discovery platform, anticipated progress and plans, results and timelines for our programs and studies, financial and accounting-related matters, as well as statements regarding our cash position. We wish to caution you that such statements reflect only the company's current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, and we refer you to our SEC filings for more details on these risks, including the company's most recent Annual Report on Form 20-F. The company undertakes no obligation to update projections and forward-looking statements in the future.